Below are the most recent publications written about "beta-Lactamases" by people in Profiles.
-
Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143.
-
Karlowsky JA, Hackel MA, Stone GG, Sahm DF. In Vitro Activity of Ceftibuten-Avibactam against ?-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134622.
-
Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0128122.
-
Karlowsky JA, Wise MG, Hackel MA, Pevear DC, Moeck G, Sahm DF. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-?-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection. Antimicrob Agents Chemother. 2022 11 15; 66(11):e0093422.
-
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257.
-
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.
-
Sun Z, Su L, Cotroneo N, Critchley I, Pucci M, Jain A, Palzkill T. Evaluation of Tebipenem Hydrolysis by ß-Lactamases Prevalent in Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2022 May 17; 66(5):e0239621.
-
Karlowsky JA, Bouchillon SK, Benaouda A, Soraa N, Zerouali K, Mohamed N, Alami T, Sahm DF. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. J Glob Antimicrob Resist. 2022 09; 30:23-30.
-
Karlowsky JA, Lob SH, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF. Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. Int J Antimicrob Agents. 2022 Mar; 59(3):106535.
-
Karlowsky JA, Kazmierczak KM, Valente MLNF, Luengas EL, Baudrit M, Quintana A, Irani P, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Braz J Infect Dis. 2021 Nov-Dec; 25(6):101647.